ADBE vs LLY: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
Adobe Inc. · Technology
$248.16
+45.0% upside to fair value
High Conviction
Grade B
VS
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(14.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
LLY |
| Current Price |
$248.16 |
$934.34 |
| Fair Value Estimate |
$359.82 |
$1,098.43 |
| Upside to Fair Value |
+45.0%
|
+17.6%
|
| Market Cap |
$101.2B |
$882.8B |
| Forward P/E |
14.1x
|
33.1x
|
| EV / EBITDA |
—
|
27.9x
|
| Price / Sales |
4.1x
|
12.2x
|
| Price / FCF |
9.8x
|
65.0x
|
| Revenue Growth YoY |
+3.3%
|
+55.5%
|
| Gross Margin |
89.1%
|
82.7%
|
| Operating Margin |
36.6%
|
46.3%
|
| Return on Equity |
62.3%
|
101.3%
|
| Dividend Yield |
— |
0% |
| FCF Yield |
10.2%
|
1.54%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
| Metric |
ADBE |
LLY |
| Zone Low |
$269.87 |
$823.82 |
| Zone High |
$305.85 |
$933.67 |
| In Buy Zone? |
Yes
|
No
|